Firms to collaborate closely to help wealth management enterprises optimize new and existing fee revenue to unlock opportunities for accelerated organic growth

NEW YORK, Oct. 8, 2026 /PRNewswire/ — Ascentix Partners (“Ascentix”), a leading strategy consultancy focused on driving wealth management enterprise growth, and PureFacts Financial Solutions (PureFacts), a leading provider of revenue management software, today announced a strategic partnership where the two firms will combine their expertise and vision to redefine revenue optimization for wealth management firms.

Together, Ascentix and PureFacts will deliver a powerful combination of technology, advisory support and private equity expertise. PureFacts’ tools and Ascentix’s insights will enable enterprises across the wealth management space to maximize transparency, efficiency and growth across fees, billing, compensation and practice management.

“There is ever-increasing demand from private equity sponsors for their RIA portfolio companies to achieve aggressive growth targets,” said Larry Roth, Founder & Managing Partner of Ascentix. “Historically, solutions for addressing these growth expectations have been restricted to a combination of asset growth, cost cutting and client acquisition.”

Roth continued, “PureFacts fundamentally transforms this picture by adding a new and powerful component to driving valuations: By considering revenue more holistically and finding overlooked or underutilized earning levers to pull.”

Fees & Billing, Advisor Compensation and Practice Management for Wealth Managers

PureFacts helps wealth and asset management firms accelerate profitable organic growth by managing the revenue lifecycle as one connected process. Through the PureRevenue Platform and its Revenue Book of Record, firms can improve pricing discipline, ensure revenue reflects the value they deliver, reduce the revenue typically lost to fee billing inefficiencies and gain the intelligence to manage revenue performance with greater confidence.

PureRevenue brings together three connected capabilities: Fees & Billing helps firms calculate, govern and capture complex fee revenue accurately, with zero tolerance for avoidable errors. Advisor Compensation aligns incentives with firm strategy, helping firms pay advisors accurately, reduce disputes and reinforce the behaviors that drive profitable growth. Practice Management gives advisors and leaders explainable intelligence across client value, loyalty, pricing, benchmarks and practice effectiveness, helping firms strengthen relationships, reduce unnecessary discounting and capture more revenue from the business already in the book.

“Organic growth is the defining challenge in wealth and asset management today, and few understand it as deeply as Ascentix and PureFacts do together,” said Pete Hess, President of PureFacts. “This partnership puts that understanding to work for the industry’s leading firms by helping them improve pricing, capture more earned revenue, align advisor behavior and use trusted revenue intelligence to accelerate profitable growth. We’re thrilled to work with Ascentix as one of the foremost experts on growth in the wealth management industry.”

About PureFacts

PureFacts is the leader in the Revenue Performance Management category for wealth and asset management firms. The PureRevenue Platform helps organizations maximize revenue potential by connecting pricing, billing, compensation, advisor behavior and AI-powered intelligence within a single Revenue Book of Record. By transforming fragmented revenue processes into a coordinated growth system, firms gain greater visibility, stronger pricing discipline, improved revenue capture and more effective advisor alignment. The result is faster organic growth, improved profitability and increased enterprise value. For more than 25 years, PureFacts has helped leading financial institutions turn revenue from an operational process into a strategic advantage. For more information, please visit https://purefacts.com/.

About Ascentix Partners

Ascentix Partners is the leading strategy consultancy focused on driving growth for wealth management enterprises. Headquartered in New York City and with a significant presence in Los Angeles, Ascentix Partners delivers growth planning, M&A consulting, strategic relationship development and brand elevation to RIA enterprises, dual registrant firms, family offices, wealthtech platforms and private market solutions providers across the country. For more information, please visit https://www.ascentix.com/.

Media Contacts

Mitch Manning or Donald Cutler
Haven Tower Group
424 317 4858 or 414 317 4864
mmanning@haventower.com or dcutler@haventower.com

View original content:https://www.prnewswire.com/news-releases/ascentix-and-purefacts-announce-strategic-partnership-to-transform-revenue-optimization-for-wealth-enterprises-302901886.html

SOURCE Ascentix Partners

The Endeavor® adds the fastest high-content cellular data generation to Ginkgo’s around-the-clock research 

PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ — Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli’s Endeavor® high-content imaging instrument into Nebula, Ginkgo’s autonomous lab in Boston. The Endeavor, the world’s fastest high-content imaging system, brings cellular imaging with real-time analysis to Nebula’s existing technologies, giving researchers the large, curated datasets needed to train and validate drug discovery AI models. 

Nebula is built on Ginkgo’s Reconfigurable Automation Carts (RACs). Each RAC is a modular unit that combines robotic arms, automated sample transport, and unified control software, so instruments can be added or rearranged as workflows change. Every day, dozens of scientists use the 100+ RACs on Nebula for real research, submitting protocols and getting their data the next day. Nebula does the work of many scientists autonomously and in parallel, running day and night and using around a third of the space as a traditional lab bench would need for the same work. . 

Imaging a 1536-well plate in under four minutes, the Endeavor is integrated into Nebula’s RAC-based system and runs continuously alongside its always-on experiments. With Araceli’s ClaireRT™ software, the Endeavor analyzes every well as the image is captured. When a well falls outside defined criteria, the system can alert operators or Nebula, or halt imaging so issues are addressed before the experiment continues. 

“The next generation of AI in drug discovery needs a completely different scale of biological data,” said Matt Beaudet, President and CEO of Araceli Biosciences. “The lab itself is changing. It now generates cellular data, interprets what it sees, and responds in real time. Ginkgo is doing that with Nebula, and Araceli brings high content imaging and real-time analysis into that loop at massive scale.” 

“An autonomous lab gets more valuable every time you add a best-in-class instrument to it,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “With your own autonomous lab, any of your scientists can access the Endeavor’s best-in-class high-content imaging and connect it effortlessly to all of your other instruments. That’s what you get with an autonomous lab: the best tools in biology, connected into one system on the same software, running your experiments 24/7.”

About Araceli Biosciences: Araceli Biosciences develops the world’s fastest high-content imaging instruments and AI-powered analysis software for automated, AI-driven labs. Its integrated solutions deliver real-time cellular insights that let automated workflows check quality and make decisions at every stage of an experiment, helping biotech and pharma organizations scale discovery faster and with greater confidence. Learn more at aracelibio.com. 

About Ginkgo Bioworks: Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo’s in-house autonomous lab is also available as a “cloud lab” through our Datapoints and Solutions contract research services. For more information, visit ginkgo.bio or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.Ginkgo Bioworks develops autonomous laboratory infrastructure and biological data generation services to make experimental science more scalable and accessible. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. 

Forward-Looking Statements of Ginkgo Bioworks: This announcement contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo’s autonomous labs. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this announcement, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, and (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this announcement. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 26, 2026, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Araceli Biosciences Investor and Media Contact: corporaterelations@aracelibio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/araceli-biosciences-and-ginkgo-bioworks-bring-cellular-imaging-at-scale-to-nebulas-lab-in-the-loop-302901742.html

SOURCE Araceli Biosciences

Arm-based E1L delivers full DPU offload from 25 watts, on the same open software as the 800G E1

SAN JOSE, Calif. and TEL AVIV, Israel, Oct. 8, 2026 /PRNewswire/ — Xsight Labs today announced the E1L, the newest member of its E-Series data processing unit (DPU) portfolio. The E1L brings fully programmable DPU capability, at up to 200G, to as little as 25 watts TDP (15 watts typical) in its eight-core, 100G configuration, powered by Arm® Neoverse® N2 cores and designed for edge, embedded and other power-constrained infrastructure. Like the E1, it is built on open standards and runs standard software without proprietary licensing, and with full cross platform compatibility, software written for one, runs on the other.

For operators, bringing DPU offload into a power-constrained site has meant a proprietary software stack sized for one chip, or leaving offload out. The E1L changes that: full DPU offload from 25 watts, on the same architecture and software as the 800G E1, so an offload written once runs from a 25-watt DPU at the edge to an 800G DPU in the data center, on standard Linux tools and with no proprietary licensing.

AI is shifting from models that answer questions to agents that take action. Every agent query, lookup and tool call becomes traffic to databases, storage and the network, and that infrastructure work lands on the same host CPUs meant for the AI workload. Agents touching critical systems also raise the bar for isolation. The E1L takes that infrastructure work off the host, fully or in part, and runs it in a separate, isolated domain, at a power envelope that fits sites outside the data center.

The E1L is scheduled to begin sampling in the second quarter of 2027.

Open, programmable silicon for the modern data center
Unlike conventional network interfaces, DPUs offload networking, security and storage tasks from the main server CPU. A network interface card moves data; a DPU also carries its own processors and memory and runs the infrastructure software itself. By building on open standards, Xsight Labs provides a fully programmable, merchant-silicon alternative to proprietary DPUs, one that accelerates software-defined infrastructure without proprietary architectures or licensing.

The E1L: low-power DPU for edge and embedded systems
Engineered for space- and power-constrained environments and for embedded applications, where specialized data center cooling is limited or absent, the E1L brings fully programmable DPU capability, at up to 200 Gbps, with TDP from 25 W to 40 W and typical draw of 15 to 25 W. The power figure starts with the silicon: the E1L is built on TSMC’s N5 process, the same node as the E1, so it does the same work in a smaller form factor, with less energy and less heat.

Built on Arm Neoverse CSS N2 and designed for Arm SystemReady compatibility, the E1L runs standard Linux and familiar software frameworks including XDP, DPDK and SPDK, so infrastructure teams can develop and deploy programmable networking, storage and security services without a proprietary software environment. The E1L is offered as a discrete device, a COM Express module and a 1RU server, all sharing the same software and feature set. Alongside the 800G E1, which draws under 75 W, the E1L completes an E-Series that runs one software stack from 100G at the edge to 800G in the core.

E1L key specifications

Compute: 8, 16 or 22 Arm Neoverse N2 coresNetworking: up to 200 Gbps over 4 SerDes lanesMemory: up to 2 DDR5-5200 interfaces with inline encryptionSecurity: line-rate AES-GCM for IPsec offloadHost interface: 20 PCIe Gen5 lanes across 6 dual-mode controllers with SR-IOV supportPower: configurable 25 W, 30 W and 40 W TDP (typical draw 15 W, 18 W and 25 W)Software: off-the-shelf Linux distributions; XDP, DPDK and SPDK integration

“The E-Series now scales from 100 gigabits at the edge to 800 gigabits in the core on a unified architecture and software stack. Operators told us they needed DPU capability within the power envelopes they already rely on. The E1L delivers that,” said Yossi Meyouhas, CEO of Xsight Labs.

“AI infrastructure is expanding across a broader range of environments, making performance per watt and software flexibility critical for deployment. By building on Arm Neoverse CSS N2, Xsight Labs is bringing programmable, efficient compute from the edge to the data center while giving developers the benefits of a common software ecosystem,” said Eddie Ramirez, Vice President of Go-To-Market, Cloud AI, Arm.

Availability
The E1L is scheduled to begin sampling in the second quarter of 2027. Xsight Labs will present the E1L at the 2026 Open Compute Project (OCP) Global Summit, October 12 to 15, in San Jose, as an OCP Bronze member.

About Xsight Labs
Xsight Labs is a leading fabless semiconductor company providing intelligent connectivity solutions for next-generation hyperscale, edge and AI data center networks. Xsight Labs’ technology delivers exponential bandwidth growth and unmatched versatility while lowering power and total cost of ownership. Founded in 2017, Xsight Labs is headquartered in Tel-Aviv, Israel, with additional offices in Kiryat Gat and Haifa, and international offices in Boston, Raleigh, and San Jose in the United States, as well as in Yerevan, Armenia. For additional information, visit www.xsightlabs.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/xsight-labs-expands-e-series-dpu-portfolio-with-the-e1l-a-fully-programmable-dpu-starting-at-25-watts-302901295.html

SOURCE xsight labs